2.420USDMkt Cap: 57.90M USDP/E: —Last update: 2026-05-21
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synth…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap57.90M USD
Enterprise Value49.77M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.23M USD
Revenue/Share—
Last Price2.420 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.85
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B15.13
EPS (TTM)-0.98
EPS (Forward)-0.85
52W Range
2.32449% of range2.520
52W High2.520 USD
52W Low2.324 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-280.51%
ROA-158.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-20.45%
Net Debt-8.13M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.80
Quick Ratio1.72
Book Value/Sh0.1600 USD
Cash/Share0.3400 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)9.977 USD
Target Range5.000 USD – 14.91 USD
# Analysts4
Ownership
Shares Out.23.93M
Float8.57M
Insiders15.36%
Institutions58.16%
Short Interest
Short Ratio4.6d
Short % Float9.24%
Short % Out.4.00%
Shares Short947.78K
Short (prev mo.)653.20K
Technical
SMA 502.542 (-4.8%)
SMA 2005.427 (-55.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)112.55K
Avg Vol (10d)143.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—